Pharmafile Logo
Pharmafocus logo
Advanced Search

Zolgensma

Showing 14 posts of 14 posts found.

novartis_outside_1

Novartis unveils strong Phase 3 efficacy for one-time therapy Zolgensma in paediatric spinal muscular atrophy

October 1, 2020
Research and Development Novartis, Zolgensma, spinal muscular atrophy

Novartis has lifted the curtain on new Phase 3 data from an ongoing trial of 33 participants on the efficacy …

News
novartis_outside_1

Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy

March 25, 2020
Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy

Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …

News

Japan approves Novartis’ Zolgensma for spinal muscular atrophy in patients under two years old

March 19, 2020
Sales and Marketing Japan, Novartis, Zolgensma, pharma, spinal muscular atrophy

Novartis has revealed that its gene therapy Zolgensma (onasemnogene abeparvovec) has secured approval from Japan’s Ministry of Health, Labour and …

News

Novartis plans giveaways of world’s most expensive drug

December 19, 2019
Business Services Novartis, Zolgensma, sma

Novartis plans to giveaway 50 doses of the world’s costliest single-dose treatment, Zolgensma, for babies under 2 years old, with …

News

FDA slams brakes on trial for world’s most expensive drug following safety concerns in children

October 30, 2019
Research and Development FDA, Novartis, Zolgensma, pharma

The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …

News
novartis_outside_1

British baby’s death not caused by Zolgensma says Novartis

September 19, 2019
Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy

Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …

News

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …

News
novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News
25482028522_7a08ece5bb_z1

Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal

August 13, 2019
Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc

Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …

News

Senators call on FDA to use “forceful response” against Novartis over faulty data scandal

August 12, 2019
Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma

Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …

News
novartis_window

Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

August 7, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …

News
novartis_window

Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …

News

Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy

April 18, 2019
Research and Development Novartis, Zolgensma, pharma

Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene …

News

Latest content

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023

Eli Lilly to acquire POINT Biopharma

October 4, 2023

Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment

October 3, 2023

WHO recommends new vaccine for prevention of malaria in children

October 3, 2023

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023